**7. Conclusions**

Radiotherapy continues to be an effective palliative treatment approach in the management of bone disease in MM patients inducing an analgesic effect in osteolytic lesions, promoting recalcification in the sites of impending pathological fractures and controlling the symptoms in spinal cord compression without significant toxicity. No difference in the efficacy for pain relief and recalcification has been observed using different radiotherapy regimens. However, the choice of radiotherapy regimen in the treatment of spinal cord compression should be based on the expectancy of patient's survival. Multi-fraction regimens, which result in a better local control, are the preferred treatment for patients with a more favourable survival prognosis.

[6] Adamietz IA, Schober C, Schulte RW, Peest D, Renner K. Palliative radiotherapy in

The Role of Radiology and Radiotherapy for Multiple Myeloma

http://dx.doi.org/10.5772/intechopen.75397

175

[7] Balducci M, Chiesa S, Manfrida S, Rossi E, Za T, et al. Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: Long-term experience. Strahlentherapie

[8] Bosch A, Frias Z. Radiotherapy in the treatment of the multiple myeloma. International

[9] Yaneva MP, Goranova-Marinova V, St G. Palliative radiotherapy in patients with mul-

[10] Leigh BR, Kurtts TA, Mack CF, Matzner MB, Shimm DS. Radiation therapy for the palliation of multiple myeloma. International Journal of Radiation Oncology, Biology,

[11] Minowa Y, Sasai K, Ishigaki T, Nagata Y, Hiraoka M. Palliative radiation therapy for multiple myeloma. Nihon Igaku Hōshasen Gakkai Zasshi. 1996;**56**:1056-1060

[12] Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, et al. Role of radiotherapy in the

[13] Manfrida S, Chiesa S, Rossi E et al. Impact of radiotherapy on pain relief and recalcification in patients affected by plasma cell neoplasms: a long term experience. Journal of

[14] Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;

[15] Reyes-Gibby CC, Wang J, Spitz M, Wu X, Yennurajalingam S, et al. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. Journal of Pain and Symptom Management. 2013;**46**:161-172 [16] Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. The Lancet Oncology. 2008;**9**:777-785

[17] Terpos E, Berenson J, Raje N, Roodman GD. Management of bone disease in multiple

[18] Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. The

[19] Terpos E, Dimopoulos MA, Moulopoulos LA. The role of imaging in the treatment of patients with multiple myeloma in 2016. American Society of Clinical Oncology

[20] Princewill K, Kyere S, Awan O, Mulligan M. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Investigation. 2013;**31**(3):

myeloma. Expert Review of Hematology. 2014;**7**(1):113-125

Lancet Oncology. 2014;**15**(12):e538-e548

Educational Book. 2016;**35**:e407-e417

treatment of multiple myeloma. Strahlenther. Oncologia. 2000;**176**:506-512

plasma cell myeloma. Radiotherapy and Oncology. 1991;**20**:111-116

Journal of Radiation Oncology, Biology, Physics. 1988;**15**:1363-1369

und Onkologie. 2011;**187**:114-119

Physics. 1993;**801-4**(25):25

**11**:279-292

206-211

tiple myeloma. Journal of BUON. 2006;**11**:43-48

Clinical Oncology. 2010;**28**(suppl): abstr e18558
